Health Condition 1: N184- Chronic kidney disease, stage 4 (severe)
Conditions
Interventions
None listed
Sponsors
Abbott Healthcare Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with age >= 18 years and 2. Patients who provide written consent/patient authorization form (PAF) for participation in thestudy 3. Patients diagnosed with CKD stages 2, 3A, 3B, or 4 (as per CKD Clinical Practice Recommendations for Primary Care Physicians and Healthcare Providers27) along with elevated levels of SUA ( > 7 mg/dL [420 μM] in men and > 6 mg/dL [360 μM] in women26)
Exclusion criteria
Exclusion criteria: Patients meeting any of the following criteria will not be included in the study: 1. Patients with reduced life expectancy (e.g., less than 6 months) due to recent diagnosis of advanced cancer (e.g., within last 2 years) and other life-threatening conditions 2. Patients with a mental condition rendering them unable to understand the nature, scope, and possible consequences of the study 3. Patients actively enrolled in another interventional study 4. Patients who are unwilling to adhere to protocol requirements 5. Pregnant and lactating females 6. Patients with comprehension disorder(s) making it impossible to understand the protocol 7. Patients with chronic disease requiring long
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| patients with HU in CKD stages 2, 3A, 3B or 4, Demographics of patients, Lifestyle habits, Comorbidities such as Diabetes, Hypertension and other, CKD patients withy Duration â?¤ 2 years, 2-5 years, 5 years, SUA level- 6-8 mg/dl, â?¢8-10 mg/dL, 10 mg/dLTimepoint: Baseline- followup period 3,6,12,18,24 month | — |
Secondary
| Measure | Time frame |
|---|---|
| a.Urate lowering drugs (allopurinol, febuxostat, and others) b.Lifestyle modification c.Urate lowering drugs and lifestyle modification. 2.Impact of HU treatment) in terms of changes in levels of kidney function test parameters. 3.Reduction in mean SUA levels after treatment with 1) urate lowering therapy vs lifestyle modification, and 2) Febuxostat versus Allopurinol. Timepoint: Baseline- followup period 3,6,12,18,24 Month | — |
Countries
India
Contacts
Public ContactSneha Nair
Abbott Healthcare Pvt. ltd., Mumbai
Outcome results
None listed